Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing

Abstract For oncology drugs that were approved by the US Food and Drug Administration (FDA) and required pharmacogenomic biomarker testing, we describe 1) the use of enrichment (biomarker-positive patients) and a randomized controlled design by pre-approval trials and 2) the treatment-by-biomarker i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alexandre Vivot, Isabelle Boutron, Geoffroy Béraud-Chaulet, Jean-David Zeitoun, Philippe Ravaud, Raphaël Porcher
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/10e6c33733934ac4b2290db95aebb496
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:10e6c33733934ac4b2290db95aebb496
record_format	dspace
spelling	oai:doaj.org-article:10e6c33733934ac4b2290db95aebb4962021-12-02T12:32:27ZEvidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing10.1038/s41598-017-07358-72045-2322https://doaj.org/article/10e6c33733934ac4b2290db95aebb4962017-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-07358-7https://doaj.org/toc/2045-2322Abstract For oncology drugs that were approved by the US Food and Drug Administration (FDA) and required pharmacogenomic biomarker testing, we describe 1) the use of enrichment (biomarker-positive patients) and a randomized controlled design by pre-approval trials and 2) the treatment-by-biomarker interaction. From the 137 drugs included in the FDA table, we selected the 22 oncology drugs with required genetic testing in their labels. These drugs corresponded to 35 approvals supported by 80 clinical studies included in the FDA medical officer reviews of efficacy. For two thirds of approvals (24/35, 69%), all clinical studies were restricted to biomarker-positive patients (enriched). Among the 11 remaining approvals with at least one non-enriched trial, for five approvals, the non-enriched studies were non-randomized. The treatment-by-biomarker interaction was statistically significant for three approvals and missing for two. Among the six approvals with a non-enriched randomized controlled trial, three featured a statistically significant treatment-by-biomarker interaction (p < 0.10), for an enhanced treatment effect in the biomarker-positive subgroup. For two thirds of FDA approvals of anticancer agents, the requirement for predictive biomarker testing was based on clinical development restricted to biomarker-positive patients. We found only few cases with clinical evidence that biomarker-negative patients would not benefit from treatment.Alexandre VivotIsabelle BoutronGeoffroy Béraud-ChauletJean-David ZeitounPhilippe RavaudRaphaël PorcherNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Alexandre Vivot Isabelle Boutron Geoffroy Béraud-Chaulet Jean-David Zeitoun Philippe Ravaud Raphaël Porcher Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing
description	Abstract For oncology drugs that were approved by the US Food and Drug Administration (FDA) and required pharmacogenomic biomarker testing, we describe 1) the use of enrichment (biomarker-positive patients) and a randomized controlled design by pre-approval trials and 2) the treatment-by-biomarker interaction. From the 137 drugs included in the FDA table, we selected the 22 oncology drugs with required genetic testing in their labels. These drugs corresponded to 35 approvals supported by 80 clinical studies included in the FDA medical officer reviews of efficacy. For two thirds of approvals (24/35, 69%), all clinical studies were restricted to biomarker-positive patients (enriched). Among the 11 remaining approvals with at least one non-enriched trial, for five approvals, the non-enriched studies were non-randomized. The treatment-by-biomarker interaction was statistically significant for three approvals and missing for two. Among the six approvals with a non-enriched randomized controlled trial, three featured a statistically significant treatment-by-biomarker interaction (p < 0.10), for an enhanced treatment effect in the biomarker-positive subgroup. For two thirds of FDA approvals of anticancer agents, the requirement for predictive biomarker testing was based on clinical development restricted to biomarker-positive patients. We found only few cases with clinical evidence that biomarker-negative patients would not benefit from treatment.
format	article
author	Alexandre Vivot Isabelle Boutron Geoffroy Béraud-Chaulet Jean-David Zeitoun Philippe Ravaud Raphaël Porcher
author_facet	Alexandre Vivot Isabelle Boutron Geoffroy Béraud-Chaulet Jean-David Zeitoun Philippe Ravaud Raphaël Porcher
author_sort	Alexandre Vivot
title	Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing
title_short	Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing
title_full	Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing
title_fullStr	Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing
title_full_unstemmed	Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing
title_sort	evidence for treatment-by-biomarker interaction for fda-approved oncology drugs with required pharmacogenomic biomarker testing
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/10e6c33733934ac4b2290db95aebb496
work_keys_str_mv	AT alexandrevivot evidencefortreatmentbybiomarkerinteractionforfdaapprovedoncologydrugswithrequiredpharmacogenomicbiomarkertesting AT isabelleboutron evidencefortreatmentbybiomarkerinteractionforfdaapprovedoncologydrugswithrequiredpharmacogenomicbiomarkertesting AT geoffroyberaudchaulet evidencefortreatmentbybiomarkerinteractionforfdaapprovedoncologydrugswithrequiredpharmacogenomicbiomarkertesting AT jeandavidzeitoun evidencefortreatmentbybiomarkerinteractionforfdaapprovedoncologydrugswithrequiredpharmacogenomicbiomarkertesting AT philipperavaud evidencefortreatmentbybiomarkerinteractionforfdaapprovedoncologydrugswithrequiredpharmacogenomicbiomarkertesting AT raphaelporcher evidencefortreatmentbybiomarkerinteractionforfdaapprovedoncologydrugswithrequiredpharmacogenomicbiomarkertesting
_version_	1718394021462671360

Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing

Ejemplares similares